英文名称:(1-BENZYLPYRROLIDINE-2,5-DIYL)DIMETHANOL | 92197-46-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 英文名称:(1-BENZYLPYRROLIDINE-2,5-DIYL)DIMETHANOL
• 中文别名: (1-苄基吡咯烷-2,5-二基)二甲醇；1-苄基-2,5-双(羟基甲基)吡咯烷；1-苄基-2,5-二羟甲基吡咯烷
• 英文名称: 1-Benzyl-2,5-bis-hydroxymethyl-pyrrolidin
• 英文别名: (1-benzyl-5-hydroxymethyl-pyrrolidine-2-yl)-methanol；[1-benzyl-5-(hydroxymethyl)pyrrolidin-2-yl]methanol
• CAS: 92197-46-1
• 化学式: C₁₃H₁₉NO₂
• 分子量: 221.299
• InChiKey: KDHJNPHFSBLEMM-UHFFFAOYSA-N

物化性质

• 沸点：
  358.7±12.0 °C(Predicted)
• 密度：
  1.133±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  43.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  英文名称:(1-BENZYLPYRROLIDINE-2,5-DIYL)DIMETHANOL 在 palladium 10% on activated carbon 盐酸 、 磺酰氯 、 氢气 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 甲醇 、 二乙二醇二甲醚 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 41.0h， 生成 2-(4-fluoro-phenyl)-2,5-diaza-bicyclo[2.2.2]octane hydrochloride
  参考文献：
  名称：

  Diazabicyclooctane derivatives and therapeutic uses thereof

  摘要：

  公开号：

  EP1178047B1
• 作为产物：
  描述：

  1-benzyl-pyrrolidine-2,5-dicarboxylic acid, 2-ethyl ester, 5-methyl ester 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 生成 英文名称:(1-BENZYLPYRROLIDINE-2,5-DIYL)DIMETHANOL
  参考文献：
  名称：

  Diazabicyclooctane derivatives and therapeutic uses thereof

  摘要：

  公开号：

  EP1178047B1

文献信息

• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSÉS CHIMIQUES
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2010120854A1

  公开（公告）日：2010-10-21

  The invention is directed to to substituted indazole derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R1 - R6 and X are defined herein. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of disorders characterized by constitutively activated ACG kinases such as cancer and more specifically leukemia and cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及取代吲唑衍生物。具体而言，本发明涉及根据公式I的化合物：其中R1-R6和X在此定义。本发明的化合物是PDK1的抑制剂，可用于治疗由组成性激活的ACG激酶（如癌症，特别是白血病、乳腺癌、结肠癌和肺癌）引起的疾病。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步涉及使用本发明化合物或包含本发明化合物的药物组合物来抑制PDK1活性和治疗相关疾病的方法。
• [EN] AZA NUCLEOSIDES, PREPARATION THEREOF AND USE AS INHIBITORS OF RNA VIRAL POLYMERASES<br/>[FR] AZANUCLEOSIDES, LEUR PREPARATION ET LEUR UTILISATION COMME INHIBITEUR DES ARN POLYMERASES VIRALES
  申请人：BIOCRYST PHARM INC

  公开号：WO2006002231A1

  公开（公告）日：2006-01-05

  Compounds represented by the formula: (I), and pharmaceutically acceptable salts thereof and prodrugs thereof; wherein Rl is H, CH3, C2H5, C3H7 R2 is H, CH3, C2H5, C3H7, CH=CH2, CH2-OH, CH2F, CF3 R'2 is H, OH, NH2, NH-alkyl, F, N3, OCH3, O-C(O)CH(NH2)alkyl R3 is H, CH3, C2H5, C3H7 R'3 is H, OH, NH2, NH-alkyl, F, N3, OCH3, O-C(O)CH(NH2)alkyl R4 is H, CH3, C2H5, C3H7 At least one of R2, R3, or R4 has to be other than H, when X=NH in B R6 is H, CH3, C2H5, -C-CH3 R7 is selected from H, alkyl, alkenyl, aryl, acyloxyalkyl, and pivaloyloxyalkyl, aminoacids, CH2CH2SC(O)alkyl; and B is represented by the following structure: X is independently NR6, O, S, R8 and R9 independently is H, NH2, OH, SH, F, Cl, Br, I, aryl, heterocycle, alkyl, alkene, alkyne, S-alkyl, S-aryl, S(O)-alkyl, SO2-alkyl, SO2NH2, SO2NH-alkyl, SO2NH-aryl, NH-alkyl, NH-aryl, N(alkyl)2, N(aryl)2, O-alkyl, O-aryl, O-heterocycle, NH-(CH2)n-aryl, NH-C(O)-alkyl, NH-C(O)-aryl are useful for inhibiting viral RNA polymerases and treating patients suffering from diseases caused by various RNA viruses.

  由以下公式表示的化合物：(I)，以及其药用盐和前药；其中R1为H，CH3，C2H5，C3H7；R2为H，CH3，C2H5，C3H7，CH=CH2，CH2-OH，CH2F，CF3；R'2为H，OH，NH2，NH-烷基，F，N3，OCH3，O-C(O)CH(NH2)烷基；R3为H，CH3，C2H5，C3H7；R'3为H，OH，NH2，NH-烷基，F，N3，OCH3，O-C(O)CH(NH2)烷基；R4为H，CH3，C2H5，C3H7；当X=NH时，R2，R3或R4中至少有一个不是H；R6为H，CH3，C2H5，-C-CH3；R7从H，烷基，烯基，芳基，酰氧烷基，皮瓦洛氧烷基，氨基酸，CH2CH2SC(O)烷基中选择；B由以下结构表示：X独立地为NR6，O，S；R8和R9独立地为H，NH2，OH，SH，F，Cl，Br，I，芳基，杂环，烷基，烯烃，炔烃，S-烷基，S-芳基，S(O)-烷基，SO2-烷基，SO2NH2，SO2NH-烷基，SO2NH-芳基，NH-烷基，NH-芳基，N(烷基)2，N(芳基)2，O-烷基，O-芳基，O-杂环，NH-(CH2)n-芳基，NH-C(O)-烷基，NH-C(O)-芳基对抑制病毒RNA聚合酶并治疗由各种RNA病毒引起的疾病的患者具有用处。
• 3-Alkenyl-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid compounds
  申请人：Fujisawa Pharmaceutical Company, Ltd.

  公开号：US04923857A1

  公开（公告）日：1990-05-08

  The invention relates to an antimicrobial compound of the formula: ##STR1## in which R.sup.1 is carboxy or protected carboxy, R.sup.2 is hydroxy(lower)alkyl or protected hydroxy(lower)alkyl, R.sup.3 and R.sup.4 are each hydrogen or lower alkyl, and R.sup.5 is saturated 4 to 6-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s), saturated 5 or 6-membered heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s) or saturated 5 or 6-membered heteromonocyclic group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), wherein said aliphatic heterocyclic group may be substituted by one or more suitable substituent(s) selected from a group consisting of hydroxy, protected hydroxy, hydroxy(lower)alkyl, protected hydroxy(lower)alkyl, halogen, lower alkoxy, lower alkyl, lower alkoxy(lower)alkyl, imino, protected imino, lower alkylamino, protected lower alkylamino, mono(or di)-(lower)alkylcarbamoyloxy, lower alkylidene, lower alkanimidoyl and imino-protective group, or pharmaceutically acceptable salts thereof.

  本发明涉及一种抗微生物化合物，其化学式为：##STR1## 其中，R.sup.1是羧基或保护羧基，R.sup.2是羟基（较低）烷基或保护羟基（较低）烷基，R.sup.3和R.sup.4分别是氢或较低烷基，R.sup.5是饱和的4到6元杂环含有1到4个氮原子的杂单环基，饱和的5或6元杂环含有1到2个氧原子和1到3个氮原子的杂单环基，或饱和的5或6元杂环含有1到2个硫原子和1到3个氮原子的杂单环基，其中所述脂环杂环基可以被一个或多个适当的取代基所取代，所述取代基被选择自羟基，保护羟基，羟基（较低）烷基，保护羟基（较低）烷基，卤素，较低烷氧基，较低烷基，较低烷氧基（较低）烷基，亚氨基，保护亚氨基，较低烷基氨基，保护较低烷基氨基，单（或二）-（较低）烷基氨基甲酰氧基，较低烷基亚烯基，较低烷基亚胺基和亚氨基保护基组成的一组中的一个或多个适当的取代基所选，或其药学上可接受的盐。
• An improved and scalable process for 3,8-diazabicyclo[3.2.1]octane analogues
  作者：Long Jiang Huang、Da Wei Teng

  DOI：10.1016/j.cclet.2010.11.030

  日期：2011.5

  An improved and scalable process for substituted 3,8-diazabicyclo[3.2.1]octane was developed. N-Benzyl-2,5-dicarbethoxy-pyrrolidine 2 was reduced to N-benzyl-2,5-dihydroxymethylpyrrolidine 9 and subsequently debenzylated to afford N-Boc-2,5-dihydroxymethylpyrrolidine 10. After mesylation of the diol 10 and cyclization with benzylamine, a diversity of scaffold, 3,8-diazabicyclo[3.2.1]octane analogue

  开发了一种改进的和可扩展的取代3,8-二氮杂双环[3.2.1]辛烷的方法。ñ -苄基-2,5-二乙酯基-吡咯烷2减少到ñ -苄基-2,5- dihydroxymethylpyrrolidine 9，随后脱苄基化，得到Ñ -Boc-2,5- dihydroxymethylpyrrolidine 10。二醇10甲磺酸化并用苄胺环化后，分5步以42％的总收率获得了3,8-二氮杂双环[3.2.1]辛烷类似物12的各种骨架。
• 3-alkenyl-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid compounds
  申请人：Fujisawa Pharmaceutical Company, Ltd.

  公开号：US05081237A1

  公开（公告）日：1992-01-14

  The invention relates to novel intermediate compounds for preparation of compounds of high antimicrobial activity, said intermediate compounds being of one of the formulas: ##STR1## wherein R.sup.1 is carboxy or protected carboxy, R.sup.2 is hydroxy(lower)alkyl or protected hyroxy(lower)alkyl, R.sup.3 and R.sup.4 are each hydrogen or lower alkyl, R.sup.5 is a saturated heterocyclic group, and R.sup.6 is aryl or lower alkoxy, or pharmaceutically acceptable salts thereof.

  本发明涉及用于制备高抗微生物活性化合物的新型中间体化合物，所述中间体化合物为以下公式之一：##STR1## 其中R.sup.1是羧基或保护羧基，R.sup.2是羟基（较低）烷基或保护羟基（较低）烷基，R.sup.3和R.sup.4分别是氢或较低烷基，R.sup.5是饱和杂环基，R.sup.6是芳基或较低烷氧基，或其药学上可接受的盐。